$NASDAQ:VTRS

Viatris Expands Cardiovascular Treatment Portfolio with $25M Licensing Deal from Lexicon

☀️Trending News VIATRIS INC ($NASDAQ:VTRS) is a global pharmaceutical company that focuses on providing affordable and accessible medications to patients [...]

Viatris, Regeneron Pharmaceuticals’ Stock Prices Dip Pre-Market as Investors Weigh In

🌥️Trending News Viatris Inc ($NASDAQ:VTRS)., formerly known as Mylan NV, is a leading pharmaceutical company focused on providing access to [...]

Viatris Among Top Players Driving Growth of Dydrogesterone Drug Market into 2031

☀️Trending News Viatris Inc ($NASDAQ:VTRS). is among the top players driving the growth of the dydrogesterone drug market into 2031. [...]

Viatris Inc Intrinsic Value Calculator – VIATRIS INC Reports Record Earnings for Q3 of Fiscal Year 2023

🌥️Earnings Overview For the third quarter ending on September 30, 2023 of fiscal year 2023, VIATRIS INC ($NASDAQ:VTRS) reported total [...]

Viatris Inc Intrinsic Value Calculator – Analysts Weigh in on Viatris Inc: Will It Outperform the Market?

🌥️Trending News Analysts are weighing in on Viatris Inc ($NASDAQ:VTRS), asking the question whether the company's stock will outperform the [...]

“Viatris Set to Reveal Second Quarter Earnings: A Deep Dive Into the Numbers”

🌥️Introduction: Investors and analysts around the world eagerly await Viatris' upcoming second-quarter earnings call, scheduled for August 7, 2023. With [...]

Go to Top